OXi8007
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:406314
CAS#:288847-41-6
Description:OXi8007 is a vascular disrupting agent with potential anticancer activity. OXi8007 was found to be strongly cytotoxic against selected human cancer cell lines (GI50 = 36 nM against DU-145 cells, for example). OXi8007 also demonstrated pronounced interference with tumor vasculature in a preliminary in vivo study utilizing a SCID mouse model bearing an orthotopic PC-3 (prostate) tumor as imaged by color Doppler ultrasound. OXi8007 may be useful for the treatment of cancer.
Price and Availability
OXi8007 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 406314Name: OXi8007CAS#: 288847-41-6Chemical Formula: C26H26NO10PExact Mass: 543.12943Molecular Weight: 543.46Elemental Analysis: C, 57.46; H, 4.82; N, 2.58; O, 29.44; P, 5.70
Synonym:OXi8007; OXi-8007; OXi 8007.
IUPAC/Chemical Name:sodium 2-methoxy-5-(6-methoxy-3-(3,4,5-trimethoxybenzoyl)-1H-indol-2-yl)phenyl phosphate
InChi Key:GQIZTUAJGVBAFG-UHFFFAOYSA-L
InChi Code:InChI=1S/C26H26NO10P.2Na/c1-32-16-7-8-17-18(13-16)27-24(14-6-9-19(33-2)20(10-14)37-38(29,30)31)23(17)25(28)15-11-21(34-3)26(36-5)22(12-15)35-4;;/h6-13,27H,1-5H3,(H2,29,30,31);;/q;2*+1/p-2
SMILES Code:O=P([O-])([O-])OC1=CC(C(N2)=C(C(C3=CC(OC)=C(OC)C(OC)=C3)=O)C4=C2C=C(OC)C=C4)=CC=C1OC.[Na+].[Na+]
Technical Data
Additional Information
References
1: Hadimani MB, Macdonough MT, Ghatak A, Strecker TE,Lopez R, Sriram M, Nguyen BL, Hall JJ, Kessler RJ, Shirali AR, Liu L,Garner CM, Pettit GR, Hamel E, Chaplin DJ, Mason RP, Trawick ML, PinneyKG. Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resemblingcombretastatin A-4 with application as a vascular disrupting agent. JNat Prod. 2013 Sep 27;76(9):1668-78. doi: 10.1021/np400374w. Epub2013 Sep 9. PubMed PMID: 24016002.
